Taking a new path in pain management (Amended)

iX Biopharma wants to be the first in the world to get ketamine registered in the US as an alternative to opioid - the only pain management drug administered by doctors.

Published Sun, Jul 19, 2015 · 09:50 PM

iX Biopharma

Singapore

WITH one day to go before it trades on the Catalist, late-stage specialty pharmaceutical firm iX Biopharma has already caught the eyes of interested parties.

This might have something to do with the firm's niche, which lies in the development and commercialisation of innovative therapies for pain management and male erectile dysfunction.

It has developed a fast-dissolving wafer formulation, Waferix - a technology that delivers a vast number of United States Food and Drug Administration (FDA) approved drugs that require quicker delivery or reduction in loss of drugs due to hepatic and gastrointestinal metabolism.

Its initial product development focus is on analgesics, or pain relievers.

Started in 2008, the company is in the midst of late-stage testing of three products - Wafernyl, Wafermine and PhoeniX - delivered through Waferix.…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes